All Updates

All Updates

icon
Filter
Product updates
Happify Health launches first prescription digital therapeutic treatment for MDD and GAD
Mental Health Tech
Jul 26, 2021
This week:
Funding
Matr Foods raises EUR 20 million in debt funding to build mycelium meat factory
Plant-based Meat
Today
Last week:
M&A
Platform Science to acquire Trimble's global transportation telematics business units
Truck Industry Tech
Yesterday
Funding
Whatfix raises USD 100 million in Series E funding to expand business
EdTech: Corporate Learning
Yesterday
Product updates
Sky Mavis launches cross-game onboarding solution
Web3 Ecosystem
Sep 14, 2024
Funding
Bicara Therapeutics raises USD 315 million in IPO; plans to develop lead candidate ficerafusp alfa
Precision Medicine
Sep 13, 2024
Partnerships
Massive Bio and Foundation Medicine partner to improve cancer clinical trial enrollment
Precision Medicine
Sep 13, 2024
Partnerships
Moffitt Cancer Center partners with AstraZeneca to advance oncology cell therapies
Cell & Gene Therapy
Sep 13, 2024
Product updates
Quandela launches European quantum computer in North America
Quantum Computing
Sep 13, 2024
Partnerships
IonQ achieves high qubit gate fidelity on barium development platform
Quantum Computing
Sep 13, 2024
Partnerships
Massive Bio and Foundation Medicine partner to improve cancer clinical trial enrollment
Clinical Trial Technology
Sep 13, 2024
Mental Health Tech

Mental Health Tech

Jul 26, 2021

Happify Health launches first prescription digital therapeutic treatment for MDD and GAD

Product updates

  • Happify Health, a New York-based mental health tech company, has launched “Ensemble”, the first transdiagnostic prescription digital therapeutic (PDTx) in the US to treat Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). The product will be available to patients for free with a prescription or through an investigational study. 

  • Ensemble’s software delivers cognitive behavioral therapy and mindfulness exercises The app provides patients with the tools to change negative thinking patterns and track their progress. The tool can also be integrated into physicians’ electronic health records.

  • The PDTx was not cleared by the US Food & Drug Administration but Happify was able to launch the product due to the relaxed guidance issued in April 2020. The company plans to use real-world data to apply for FDA clearance within the next 18 to 24 months. 

  • Founded in 2012, Happify Health offers a self-care app and AI-powered chatbot that helps users navigate mental health challenges. The company also develops evidence-based digital therapeutic and care delivery tools for healthcare providers, health plans, individuals, and pharmaceutical manufacturers. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.